In response to the series of severe infections and deaths from antibiotic-resistant superbug tainted duodenoscopes, FDA has released a list of reprocessing procedures that should be followed by healthcare facilities. These “infection mitigation strategies” are available in an agency safety communication released today.
“Duodenoscopes are complex instruments that contain many small working parts. Proper cleaning and disinfection of the elevator mechanism is of particular concern. The moving parts of the elevator mechanism contain microscopic, hard-to-reach crevices,” according to the FDA notice.
“If not thoroughly cleaned and disinfected, tissue or fluid and residual bacteria from one patient may remain in device crevices of a duodenoscope, exposing subsequent patients to risk of infection.”
When reprocessing duodenoscopes, FDA suggests that facility staff take the following steps:
- Microbiological Culturing
- Ethylene Oxide Sterilization
- Use of a Liquid Chemical Sterilant Processing System
- Repeat High-Level Disinfection
These measures are detailed in the safety communication notice and should be followed in conjunction with adhering the device manufacturer’s reprocessing instructions.
Related Articles
-
Trading the potential health risk to a few patients versus the collective good of all patients is never acceptable. Even the experts are voicing concerns over the effectiveness of duodenoscope reprocessing.
-
Effective February 7, the agency will conduct inspections across all commodities, as well as mission-critical foreign and domestic inspections.
-
The draft guidance proposes updates to clarify how the Breakthrough Devices Program may be applicable to certain medical devices that promote health equity, as well as considerations in designating eligible devices that may benefit populations impacted by disparities in health…
-
Perhaps now is the time to truly weigh patient outcomes versus the risks associated with the reprocessing of duodenoscopes.
